Benufutamab

Names

[ Name ]:
Benufutamab

Biological Activity

[Description]:

Benufutamab (GEN1029) is a death receptor 5 (DR5)-specific agonistic antibody. Benufutamab is a mixture of 2 noncompeting DR5-specific IgG1 antibodies, each with an E430G mutation in the Fc domain. Benufutamab has antitumor effects[1].

[Related Catalog]:

Research Areas >> Cancer

[In Vitro]

Benufutamab（GEN1029；HexaBody-DR5/DR5；20 µg/mL；24 小时）在多发性骨髓瘤 (MM) 细胞中诱导强效细胞毒性[1]。 Cell Viability Assay[1] Cell Line: Multiple myeloma (MM) cells Concentration: 20 µg/mL Incubation Time: 24 hours Result: Induced potent cytotoxicity.

[In Vivo]

Benufutamab（GEN1029；HexaBody-DR5/DR5；0.5-2 mg/kg；腹腔注射；每周一次；持续 9 周）在结直肠癌的 PDX 模型中显示出显着的抗肿瘤活性[2]。 Animal Model: Balb/c athymic nude or NU/NU nude mice injected with colorectal cancer (CRC) cells[2] Dosage: 0.5 mg/kg, or 2 mg/kg Administration: i.p.; once a week; for 9 weeks Result: Showed significant antitumor activity.

[References]

[1]. Hilma J van der Horst, et al. Potent preclinical activity of HexaBody-DR5/DR5 in relapsed and/or refractory multiple myeloma. Blood Adv. 2021 Apr 27;5(8):2165-2172.

[2]. Marije B Overdijk, et al. Dual Epitope Targeting and Enhanced Hexamerization by DR5 Antibodies as a Novel Approach to Induce Potent Antitumor Activity Through DR5 Agonism. Mol Cancer Ther. 2020 Oct;19(10):2126-2138.

Chemical & Physical Properties

No Any Chemical & Physical Properties

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.